GT Medical Technologies Launches Trailblazing BRIDGES Trial for Glioblastoma Patients

GT Medical Technologies Initiates Groundbreaking BRIDGES Trial for Glioblastoma

On January 14, 2026, GT Medical Technologies officially announced the enrollment of the first patients in the BRIDGES clinical trial. This pivotal study aims to investigate the efficacy of their innovative GammaTile technology for newly diagnosed glioblastoma (GBM) patients. Given that glioblastoma is known for its grim prognosis—with an average survival rate of less than two years—the BRIDGES trial offers a promising pathway to potentially enhance survival outcomes for those severely affected by this aggressive brain tumor.

The BRIDGES trial, formally named Beginning Radiation Immediately with GammaTile® at Glioblastoma Excision versus Standard of Care, is an innovative and randomized clinical study. It evaluates whether implanting GammaTile at the time of surgical excision is more effective in improving survival than current standards of care. With the advancement of medical technologies, trials like BRIDGES are pivotal in seeking better alternatives for patients faced with such formidable diagnoses.

Per Langoe, CEO of GT Medical Technologies, expressed pride in the early enrollments, emphasizing the vital need for disruptive therapies in combating GBM. He stated, "Patients with newly diagnosed GBM face an unacceptably poor prognosis, which highlights a significant demand for innovative treatment options that can redefine the standard of care." Langoe's optimism is further fueled by the success of their prior ROADS trial focused on newly diagnosed brain metastases, paving the way for the BRIDGES trial.

The first enrollment was carried out at Westchester Medical Center in Valhalla, New York, by neurosurgeon Dr. Simon Hanft. Dr. Hanft was enthusiastic about the trial’s potential, acknowledging the opportunities it offers to patients afflicted by GBM. He noted, "We have utilized GammaTile successfully for a number of years, and we look forward to making meaningful contributions to the BRIDGES trial. This initiative could signify a pivotal advancement in the care of patients dealing with GBM."

In a similar vein, Dr. Clark C. Chen, who heads the Brain Tumor Program at Brown University Health in Providence, Rhode Island, remarked on the ongoing progress in glioblastoma treatment. "Although glioblastoma remains a challenging disease, the BRIDGES trial exemplifies meaningful progress in this field, granting patients access to leading-edge therapies in modern neuro-oncology." Both centers exemplify how the BRIDGES trial is not simply about research, but also about hope and potential betterment of life quality.

The GammaTile therapy aims to be implanted during the GBM tumor excision process, allowing radiation treatment to commence immediately, rather than weeks after surgery. This innovative approach shifts from traditional treatment paradigms, wherein intervals between surgery and radiation present opportunities for tumor regrowth. As stated by Dr. Michael Garcia, Chief Medical Officer of GT Medical Technologies, "By delivering radiation from day one—when tumor burden is at its lowest—GammaTile provides a fresh perspective on treating GBM post-operatively. This strategy lies at the core of the BRIDGES trial's promise, potentially transforming responses to glioblastoma."

GT Medical Technologies, established by a group of dedicated brain tumor specialists, focuses on addressing unmet needs in brain tumor treatment. Their commitment to enhancing the lives of patients through innovative solutions aims at uplifting the standard of care for cognitive and oncological health.

GammaTile itself is an FDA-cleared, bioabsorbable collagen implant containing radiation seeds. Designed specifically for operable brain tumors, it delivers localized radiation directly from within, targeting remaining cancer cells immediately after tumor removal. This localized treatment not only helps prevent regrowth of cancer but also minimizes radiation exposure to adjacent healthy tissues, making it a pioneering advancement in patient care.

Since its launch in March 2020, GammaTile has gained recognition across more than 100 leading medical centers, reflecting its expanding acceptance in various healthcare settings. For additional insights into GT Medical Technologies and GammaTile, visit gammatile.com and follow their updates on social media platforms like Facebook, Instagram, LinkedIn, and X.